Results
Suven Life Sciences FY26 Net Loss Widens to ₹548.6 Crore
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting a consolidated net loss of ₹276.34 crore for the year.
Noted waiver of fines by BSE f
